Literature DB >> 22447629

Temporal compliance trends in a cluster randomization with crossover trial of out-of-hospital cardiac arrest.

Robert H Schmicker1, Brian G Leroux, Gena K Sears, Ian Stiell, Laurie J Morrison, Tom P Aufderheide, Ray Fowler, Rusty Lowe, Stanley Morrow, Ed Plumlee, Sheldon Cheskes.   

Abstract

BACKGROUND: Low compliance to randomized nondrug interventions can affect treatment estimates of clinical trials. Cluster-randomized crossover may be appropriate for increasing compliance in the out-of-hospital cardiac arrest setting.
PURPOSE: The purpose was to determine whether the elapsed time from start of a nonblinded treatment period to episode enrollment date in a cluster-randomized crossover trial is associated with compliance to either a period of brief cardiopulmonary resuscitation (CPR) with electrocardiogram (ECG) rhythm analysis or a period of longer CPR with a delayed ECG rhythm analysis in patients with out-of-hospital cardiac arrest.
METHODS: The Resuscitation Outcomes Consortium PRIMED Analyze Late (AL) versus Analyze Early (AE) trial was a cluster-randomized crossover trial at 10 North American regional sites. Clusters were created based on local service preference with treatment periods varying from 3 to 12 months depending on the expected enrollment rate of each randomizing unit. Episodes on the AL arm had a target of 180 s from CPR start to shock assessment and were deemed compliant if total time was between 150 and 210 s. Episodes on the AE arm had a target of <30 s from CPR start to shock assessment and were deemed compliant if total time was <60 s. We used logistic regression to examine the association between compliance (yes/no) and the elapsed number of days from the start of the treatment period to the episode in the framework of generalized estimating equations, controlling for randomized treatment (Late, reference = Early) and treatment period length (reference = 3, 4-5, 6, 7-11, and 12 months).
RESULTS: We had 8769 episodes in our analysis population. Overall compliance to the randomized arm was 63.5%. After adjusting for treatment arm and treatment period length, the odds of compliance for episodes occurring >300 days from treatment period start were 33% lower (odds ratio (OR): 0.67; 95% confidence interval (CI): 0.52, 0.86) than for those <60 days from treatment period start. There was no significant difference in compliance between episodes before and immediately after a cluster crossed over to the opposite arm (OR: 0.81; 95% CI: 0.57, 1.16). LIMITATIONS: A major challenge was the lack of synchronicity between training cycles and agency crossover dates.
CONCLUSION: We found a significant decrease in compliance to the AL versus AE cardiac arrest intervention as the elapsed time from start of treatment period increased. We did not find a difference in compliance immediately before and after a crossover. While these results suggest that future cluster with crossover trials in the out-of-hospital setting be designed with short treatment periods and frequent crossovers, provider logistical concerns must also be considered.

Entities:  

Mesh:

Year:  2012        PMID: 22447629      PMCID: PMC3515666          DOI: 10.1177/1740774512440636

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  9 in total

Review 1.  Intention-to-treat principle.

Authors:  V M Montori; G H Guyatt
Journal:  CMAJ       Date:  2001-11-13       Impact factor: 8.262

2.  International EMS systems: The United States: past, present, and future.

Authors:  Charles N Pozner; Richard Zane; Stephen J Nelson; Michael Levine
Journal:  Resuscitation       Date:  2004-03       Impact factor: 5.262

3.  A descriptive analysis of Emergency Medical Service Systems participating in the Resuscitation Outcomes Consortium (ROC) network.

Authors:  Daniel P Davis; Lisa A Garberson; Douglas L Andrusiek; David Hostler; Mohamud Daya; Ronald Pirrallo; Alan Craig; Shannon Stephens; Jonathan Larsen; Alexander F Drum; Raymond Fowler
Journal:  Prehosp Emerg Care       Date:  2007 Oct-Dec       Impact factor: 3.077

Review 4.  An overview of variance inflation factors for sample-size calculation.

Authors:  F Y Hsieh; Philip W Lavori; Harvey J Cohen; John R Feussner
Journal:  Eval Health Prof       Date:  2003-09       Impact factor: 2.651

5.  Resuscitation Outcomes Consortium (ROC) PRIMED cardiac arrest trial methods part 2: rationale and methodology for "Analyze Later vs. Analyze Early" protocol.

Authors:  Ian G Stiell; Clif Callaway; Dan Davis; Tom Terndrup; Judy Powell; Andrea Cook; Peter J Kudenchuk; Mohamud Daya; Richard Kerber; Ahamed Idris; Laurie J Morrison; Tom Aufderheide
Journal:  Resuscitation       Date:  2008-05-19       Impact factor: 5.262

Review 6.  First responders after disasters: a review of stress reactions, at-risk, vulnerability, and resilience factors.

Authors:  David A Alexander; Susan Klein
Journal:  Prehosp Disaster Med       Date:  2009 Mar-Apr       Impact factor: 2.040

Review 7.  Sample size in cluster randomisation.

Authors:  S M Kerry; J M Bland
Journal:  BMJ       Date:  1998-02-14

8.  Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest.

Authors:  Ian G Stiell; Graham Nichol; Brian G Leroux; Thomas D Rea; Joseph P Ornato; Judy Powell; James Christenson; Clifton W Callaway; Peter J Kudenchuk; Tom P Aufderheide; Ahamed H Idris; Mohamud R Daya; Henry E Wang; Laurie J Morrison; Daniel Davis; Douglas Andrusiek; Shannon Stephens; Sheldon Cheskes; Robert H Schmicker; Ray Fowler; Christian Vaillancourt; David Hostler; Dana Zive; Ronald G Pirrallo; Gary M Vilke; George Sopko; Myron Weisfeldt
Journal:  N Engl J Med       Date:  2011-09-01       Impact factor: 91.245

9.  Regional variation in out-of-hospital cardiac arrest incidence and outcome.

Authors:  Graham Nichol; Elizabeth Thomas; Clifton W Callaway; Jerris Hedges; Judy L Powell; Tom P Aufderheide; Tom Rea; Robert Lowe; Todd Brown; John Dreyer; Dan Davis; Ahamed Idris; Ian Stiell
Journal:  JAMA       Date:  2008-09-24       Impact factor: 56.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.